News | June 23, 2022
Glenmark Pharmaceuticals to address USFDA’s observation
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
A total of five observations for Goa and 17 for Monroe
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
The company has 47 ANDA's pending approval with the U.S.FDA
The company reports revenue growth of 26% and PAT growth of 21% YoY
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million
Subscribe To Our Newsletter & Stay Updated
